Here, we outline the current understanding of the role of HSPs, including HSP27, HSP70, and HSP90, in MPN, and summarize the recent advances in utilization of HSP inhibitors as emerging targeted therapies for MPN. Here, HSP90AA1 is linked to myeloproliferative neoplasm.